{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:50:14Z","timestamp":1792601414361,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100011789","name":"Jilin Province Science and Technology Department","doi-asserted-by":"crossref","award":["20200201591JC"],"award-info":[{"award-number":["20200201591JC"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s12325-021-01943-z","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T07:03:05Z","timestamp":1637305385000},"page":"532-543","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study"],"prefix":"10.1007","volume":"39","author":[{"given":"Xiaomeng","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangzhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junna","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken. H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4066-9473","authenticated-orcid":false,"given":"Ou","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"issue":"25","key":"1943_CR1","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","volume":"117","author":"FM Foss","year":"2011","unstructured":"Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood. 2011;117(25):6756\u201367.","journal-title":"Blood"},{"issue":"12","key":"1943_CR2","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ, Harris NL, Vose JM, et al. ALK\u2212 anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496\u2013504.","journal-title":"Blood"},{"issue":"3","key":"1943_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.critrevonc.2010.07.007","volume":"79","author":"KJ Savage","year":"2011","unstructured":"Savage KJ, Ferreri AJ, Zinzani PL, Pileri SA. Peripheral T-cell lymphoma\u2014not otherwise specified. Crit Rev Oncol Hematol. 2011;79(3):321\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"1943_CR4","doi-asserted-by":"publisher","first-page":"E562","DOI":"10.3324\/haematol.2018.213512","volume":"104","author":"D Sibon","year":"2019","unstructured":"Sibon D, Dinh-Phong N, Schmitz N, et al. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. Haematologica. 2019;104(12):E562\u20135.","journal-title":"Haematologica"},{"issue":"32","key":"1943_CR5","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","volume":"30","author":"D Sibon","year":"2012","unstructured":"Sibon D, Fournier M, Bri\u00e8re J, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte trials. J Clin Oncol. 2012;30(32):3939\u201346.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1943_CR6","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstr\u00f6m J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570\u20137.","journal-title":"Blood"},{"issue":"5","key":"1943_CR7","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/bjh.14763","volume":"178","author":"L Li","year":"2017","unstructured":"Li L, Duan W, Zhang L, et al. The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. Br J Haematol. 2017;178(5):772\u201380.","journal-title":"Br J Haematol"},{"issue":"36","key":"1943_CR8","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1200\/JCO.2017.73.8195","volume":"35","author":"MJ Maurer","year":"2017","unstructured":"Maurer MJ, Ellin F, Srour L, et al. International assessment of event-free survival at 24\u00a0months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol. 2017;35(36):4019\u201326.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1943_CR9","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1093\/annonc\/mdn399","volume":"19","author":"A Gutierrez","year":"2008","unstructured":"Gutierrez A, Rodriguez J. Value of frontline autologous stem-cell transplantation in peripheral T-cell lymphoma. Ann Oncol. 2008;19(8):1512.","journal-title":"Ann Oncol"},{"issue":"1","key":"1943_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","volume":"79","author":"J Rodriguez","year":"2007","unstructured":"Rodriguez J, Conde E, Gutierrez A, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol. 2007;79(1):32\u20138.","journal-title":"Eur J Haematol"},{"issue":"1","key":"1943_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-020-00892-4","volume":"13","author":"AC Mamez","year":"2020","unstructured":"Mamez AC, Dupont A, Blaise D, Chevallier P, Forcade E, Ceballos P, Mohty M, Suarez F, Beguin Y, Peffault De Latour R, Rubio MT, Tournilhac O, Nguyen S. Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC). J Hematol Oncol. 2020;13(1):56. https:\/\/doi.org\/10.1186\/s13045-020-00892-4.","journal-title":"J Hematol Oncol."},{"issue":"4","key":"1943_CR12","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","volume":"2","author":"J Dupuis","year":"2015","unstructured":"Dupuis J, Morschhauser F, Ghesqui\u00e8res H, et al. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study. Lancet Haematol. 2015;2(4):e160\u20135.","journal-title":"Lancet Haematol"},{"issue":"7","key":"1943_CR13","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","volume":"110","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007;110(7):2316\u201323.","journal-title":"Blood"},{"issue":"4","key":"1943_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/bjh.13855","volume":"172","author":"RH Advani","year":"2016","unstructured":"Advani RH, Ansell SM, Lechowicz MJ, et al. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial. Br J Haematol. 2016;172(4):535\u201344.","journal-title":"Br J Haematol"},{"issue":"1","key":"1943_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","volume":"14","author":"Y Shi","year":"2021","unstructured":"Shi Y, Wu J, Wang Z, et al. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). J Hematol Oncol. 2021;14(1):12.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"1943_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.annonc.2020.12.009","volume":"32","author":"HY Yhim","year":"2021","unstructured":"Yhim HY, Kim T, Kim SJ, et al. Combination treatment of copanlisib and gemcitabine in relapsed\/refractory PTCL (COSMOS): an open-label phase I\/II trial. Ann Oncol. 2021;32(4):552\u20139.","journal-title":"Ann Oncol"},{"key":"1943_CR17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.251454","author":"T Tang","year":"2020","unstructured":"Tang T, Martin P, Somasundaram N, et al. Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or naturalkiller\/T-cell lymphoma. Haematologica. 2020. https:\/\/doi.org\/10.3324\/haematol.2020.251454.","journal-title":"Haematologica."},{"issue":"8","key":"1943_CR18","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","volume":"98","author":"E Sabattini","year":"2013","unstructured":"Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98(8):e81\u20132.","journal-title":"Haematologica"},{"issue":"3","key":"1943_CR19","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/PAS.0000000000000571","volume":"40","author":"A Onaindia","year":"2016","unstructured":"Onaindia A, Martinez N, Montes-Moreno S, et al. CD30 expression by B and T cells: a frequent finding in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma-not otherwise specified. Am J Surg Pathol. 2016;40(3):378\u201385.","journal-title":"Am J Surg Pathol"},{"key":"1943_CR20","doi-asserted-by":"publisher","unstructured":"Brentuximab beats standard therapies for CTCL. Cancer Discov. 2017;7(3):OF3. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2017-012.","DOI":"10.1158\/2159-8290.CD-NB2017-012"},{"issue":"25","key":"1943_CR21","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","volume":"130","author":"B Pro","year":"2017","unstructured":"Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709\u201317.","journal-title":"Blood"},{"issue":"3","key":"1943_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41571-018-0163-3","volume":"16","author":"D Killock","year":"2019","unstructured":"Killock D. ECHELON-2\u2014brentuximab raises PTCL outcomes to new levels. Nat Rev Clin Oncol. 2019;16(3):145.","journal-title":"Nat Rev Clin Oncol"},{"key":"1943_CR23","unstructured":"Takeda China announces ADCETRIS\u00ae (brentuximab vedotin) is approved for the treatment of adult patients with CD30-positive Lymphomas. 2020. https:\/\/www.takeda.com\/newsroom\/newsreleases\/2020\/takeda-china-announces-adcetris-brentuximab-vedotin-is-approved-for-the-treatment-of-adult-patients-with-cd30-positive-lymphomas\/#:~:text=Takeda%20China%20announces%20ADCETRIS%20%C2%AE%20%28brentuximab%20vedotin%29%20is,anaplastic%20large%20cell%20lymphoma%20%28sALCL%29%20or%20Hodgkin%20lymphoma. Accessed May 2020."},{"issue":"18","key":"1943_CR24","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418\u201325.","journal-title":"Blood"},{"key":"1943_CR25","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.2147\/OTT.S189825","volume":"12","author":"S Deng","year":"2019","unstructured":"Deng S, Lin S, Shen J, Zeng Y. Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis. Onco Targets Ther. 2019;12:2335\u201342.","journal-title":"Onco Targets Ther"},{"issue":"10168","key":"1943_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340.","journal-title":"Lancet"},{"issue":"19","key":"1943_CR27","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","volume":"124","author":"C Bossard","year":"2014","unstructured":"Bossard C, Dobay MP, Parrens M, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124(19):2983\u20136.","journal-title":"Blood"},{"key":"1943_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ejca.2021.01.054","volume":"148","author":"YH Kim","year":"2021","unstructured":"Kim YH, Prince HM, Whittaker S, et al. Response to brentuximab vedotin versus physician\u2019s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis. Eur J Cancer. 2021;148:411\u201321.","journal-title":"Eur J Cancer"},{"issue":"20","key":"1943_CR29","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1182\/blood.2020005020","volume":"135","author":"T Jelinek","year":"2020","unstructured":"Jelinek T, Zuchnicka J. Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia. Blood. 2020;135(20):1816.","journal-title":"Blood"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01943-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01943-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01943-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T08:45:18Z","timestamp":1643359518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01943-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1943"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01943-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]},"assertion":[{"value":"30 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}